Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Endocrinology · Endocrine Tumors

Who Treats Endocrine Tumors? Your Care Team Explained

At a Glance

Endocrine tumors are best treated by a multidisciplinary care team that includes endocrinologists, surgical oncologists, medical oncologists, and nuclear medicine specialists. Receiving care at a specialized center with a dedicated tumor board ensures you get expert, coordinated treatment.

Because endocrine tumors can affect both your hormone levels and other organs, they are best managed by a diverse group of specialists working together. This group of experts is known as a multidisciplinary care team (MDT). Research shows that having a dedicated team of specialists who focus on your specific type of tumor improves the quality of your care, ensures your treatment aligns with the latest clinical guidelines, and even improves survival rates [1][2][3].

Key Specialists on Your Care Team

Managing an endocrine tumor requires a highly specific mix of medical expertise. Depending on the location and behavior of your tumor, your core team will likely include:

  • Endocrinologist: A doctor who specializes in hormones and glands. Many endocrine tumors are “functional,” meaning they overproduce hormones that cause symptoms throughout your body. Your endocrinologist will monitor these levels and manage symptoms. If your tumor is “non-functional” (not producing excess hormones), an endocrinologist may still be involved to monitor the overall health of your endocrine system, especially if surgery affects your gland function.
  • Surgical Oncologist: A surgeon with advanced training in removing tumors. Because endocrine glands can be delicate and deeply located, it is important to have a surgeon with specific expertise in the anatomy where your tumor is located [4][5].
  • Medical Oncologist: A doctor who specializes in treating cancer with systemic therapies, which are medications that travel throughout the body. They oversee treatments like chemotherapy, targeted therapies, or immunotherapies if needed.
  • Nuclear Medicine Specialist: A doctor who specializes in using radioactive substances for diagnosis and treatment. For a specific type of endocrine tumor known as a neuroendocrine tumor (NET), these specialists are essential for conducting precise imaging tests (such as DOTATATE PET scans) and administering Peptide Receptor Radionuclide Therapy (PRRT). PRRT is a targeted radiation treatment designed specifically for these tumors, and specialized multidisciplinary teams play a crucial role in coordinating this therapy [6][7].
  • Pathologists and Radiologists: Pathologists analyze your biopsy samples to determine how the tumor is behaving, while radiologists interpret your imaging scans.
  • Supportive Care Specialists: Your team may also include an Oncology Nurse Navigator to help coordinate your appointments and communicate between different doctors, as well as a Dietitian who can help manage symptoms like diarrhea that can occur with certain functional tumors.

The Importance of a Tumor Board

When building your care team, you should look for a treatment center that utilizes a multidisciplinary tumor board (MTB). A tumor board is a regular meeting where your team of specialists gathers to review your specific case.

During these meetings, the team reviews your scans and test results together to reach a consensus on the best treatment plan [8][9]. This collaborative approach ensures that all aspects of your health are considered and that you have access to all available treatment options [10][11].

Seeking Care at a Specialized Center

Because endocrine and neuroendocrine tumors are relatively rare, not all hospitals see enough cases to have dedicated experts on staff. Receiving care at a specialized center with an established multidisciplinary team is associated with better overall outcomes and reduces the risk of delayed or suboptimal management [12][13][14].

Finding a specialized center can feel overwhelming, but patient advocacy organizations, such as the Neuroendocrine Tumor Research Foundation (NETRF), often provide directories of experienced treatment centers. Even if you cannot receive all your day-to-day care at a major specialized center, having an expert from one of these centers consult with your local doctors can make a significant difference in your treatment plan.

Common questions in this guide

Which doctors are involved in treating endocrine tumors?
Treatment usually requires a diverse team of experts. This typically includes an endocrinologist to manage hormones, a surgical oncologist to remove the tumor, a medical oncologist for systemic therapies, and often a nuclear medicine specialist.
What is a multidisciplinary tumor board?
A tumor board is a regular meeting where your team of specialists reviews your scans and test results together. This collaborative approach helps them reach an agreement on the most effective treatment plan for your specific case.
Do I need an endocrinologist or an oncologist for my tumor?
You will likely need both. An endocrinologist monitors and manages any hormone imbalances caused by the tumor, while oncologists focus on treating, managing, or removing the tumor itself using medications or surgery.
Where is the best place to get treatment for an endocrine tumor?
Because these tumors are relatively rare, it is highly recommended to seek care at a specialized center with an established multidisciplinary team. Research shows that treatment at these experienced centers is associated with better overall health outcomes.
Do I have to travel to a specialized center for all my appointments?
Not necessarily. Many patients travel to a specialized center for their initial diagnosis and to create a treatment plan, but are able to receive their routine, day-to-day care locally in coordination with the expert team.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many cases of this specific type of endocrine tumor does this center treat annually?
  2. 2.Will my case be presented at a multidisciplinary tumor board, and who participates in those meetings?
  3. 3.Are there specialized experts, such as nuclear medicine specialists or specialized surgical oncologists, available at this hospital?
  4. 4.Who will act as the primary point of contact or care coordinator among all my different specialists?
  5. 5.If my tumor is a neuroendocrine tumor (NET), does this facility have the capability to perform DOTATATE PET scans and PRRT, or will I need a referral to a specialized center?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Current and emerging strategies for the management of advanced/metastatic lung neuroendocrine tumors.

    Rutherford M, Wheless M, Thomas K, Ramirez RA

    Current problems in cancer 2024; (49()):101061 doi:10.1016/j.currproblcancer.2024.101061.

    PMID: 38281845
  2. 2

    Does Multidisciplinary Team Management Improve Clinical Outcomes in NSCLC? A Systematic Review With Meta-Analysis.

    de Castro G, Souza FH, Lima J, et al.

    JTO clinical and research reports 2023; (4(12)):100580 doi:10.1016/j.jtocrr.2023.100580.

    PMID: 38046377
  3. 3

    The Prognostic Effect of Multidisciplinary Team Intervention in Patients with Advanced Gastric Cancer.

    Xiang YY, Deng CC, Liu HY, et al.

    Current oncology (Toronto, Ont.) 2022; (29(2)):1201-1212 doi:10.3390/curroncol29020102.

    PMID: 35200601
  4. 4

    Surgical management of pancreatic neuroendocrine tumors: an introduction.

    Hain E, Sindayigaya R, Fawaz J, et al.

    Expert review of anticancer therapy 2019; (19(12)):1089-1100 doi:10.1080/14737140.2019.1703677.

    PMID: 31825691
  5. 5

    What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Neoplasms?

    Choe J, Kim KW, Kim HJ, et al.

    Korean journal of radiology 2019; (20(1)):5-17 doi:10.3348/kjr.2018.0040.

    PMID: 30627018
  6. 6

    AIMN, ITANET, SIE joint position paper for the recognition, prevention and management of NET carcinoid syndrome and crises during peptide receptor radionuclide therapy.

    Laudicella R, Faggiano A, Pirro V, et al.

    European journal of nuclear medicine and molecular imaging 2026; (53(3)):1445-1457 doi:10.1007/s00259-025-07596-2.

    PMID: 41055768
  7. 7

    The role of multimodal treatment in patients with advanced lung neuroendocrine tumors.

    Fazio N, Ungaro A, Spada F, et al.

    Journal of thoracic disease 2017; (9(Suppl 15)):S1501-S1510 doi:10.21037/jtd.2017.06.14.

    PMID: 29201453
  8. 8

    Standardizing Surgical Management of Retroperitoneal Sarcomas: Dawn of a New Surgical Subspeciality in India.

    Patkar S, Shah TM, Agarwal J, et al.

    Annals of surgical oncology 2024; (31(8)):5433-5442 doi:10.1245/s10434-024-15467-7.

    PMID: 38762642
  9. 9

    Endocrine Tumor Board: Ten Years' Experience of a Multidisciplinary Clinical Working Conference.

    Savitz A, Fong B, Hochberg A, et al.

    The Permanente journal 2020; (24()) doi:10.7812/TPP/19.140.

    PMID: 32663125
  10. 10

    Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?

    Fazio N, La Salvia A

    Best practice & research. Clinical endocrinology & metabolism 2023; (37(5)):101794 doi:10.1016/j.beem.2023.101794.

    PMID: 37414651
  11. 11

    How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery.

    Fermi F, Andreasi V, Muffatti F, et al.

    Current oncology reports 2022; (24(2)):227-239 doi:10.1007/s11912-022-01200-8.

    PMID: 35076884
  12. 12

    Factors Influencing Costs of Cancer Care for Patients with Neuroendocrine Neoplasms.

    Weickert MO

    Neuroendocrinology 2025; (115(12)):935-956 doi:10.1159/000544050.

    PMID: 39938507
  13. 13

    Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group.

    Annals of surgical oncology 2016; (23(11)):3531-3540 doi:10.1245/s10434-016-5336-7.

    PMID: 27480354
  14. 14

    An Update on Appendiceal Neuroendocrine Tumors.

    Andrini E, Lamberti G, Alberici L, et al.

    Current treatment options in oncology 2023; (24(7)):742-756 doi:10.1007/s11864-023-01093-0.

    PMID: 37140773

This page explains the roles of various specialists in treating endocrine tumors for educational purposes only. Always consult your healthcare provider to determine the right care team for your specific diagnosis.

Get notified when new evidence is published on Tumor of endocrine glands.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.